Targeting Cancer Stem Cells and Hedgehog Pathway: Enhancing Cisplatin Efficacy in Ovarian Cancer With Metformin
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70508 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Emad Jafarzadeh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Metformin, Cisplatin, Neoplastic Stem Cells, Hedgehog Proteins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deputy of Research, Tehran University of Medical Sciences, Tehran, Iran, National Institute for Medical Research Development (NIMAD).
Abstract (Originalsprache)
Ovarian cancer (OC) remains a leading cause of gynaecological cancer deaths due to late diagnosis and the emergence of resistance to platinum‐based chemotherapy, like cisplatin (Cis). Here, we investigated the potential of metformin (Met), a drug commonly used for type 2 diabetes, to overcome Cis resistance in OC. Our findings revealed a synergistic effect of Met with Cis in inhibiting cell viability, proliferation and colony/sphere formation capacity in both cisplatin‐sensitive (A2780) and ‐resistant (A2780/CDDP) ovarian cancer cell lines. This synergistic action triggered apoptosis through DNA damage, S‐phase cell cycle arrest and modulation of autophagy. Met also significantly decreased the expression of pluripotency transcription factors (Oct‐4, Sox2 and Nanog), indicating its potential to target cancer stem cells (CSCs). Furthermore, the combination therapy downregulated multidrug resistance protein 1 (MDR1) and excision repair cross‐complementation group 1 (ERCC1) expression, thereby sensitising resistant cells to Cis‐induced cytotoxicity. Additionally, the combination treatment suppressed the Hedgehog (Hh) signalling pathway, which is an important factor in inhibiting CSCs. Our study highlights the potential of the Met signalling pathway to synergise with Cis, overcoming therapeutic resistance in OC by targeting diverse cellular processes, including CSCs, and warrants further investigation in preclinical models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
- Artificial Intelligence in Medical Sciences Research Center, Smart University of Medical Sciences, Tehran, Iran.
- Toxicology and Poisoning Research Centre, Department of Toxicology and Pharmacology, Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Emad Jafarzadeh
Förderung
- Deputy of Research, Tehran University of Medical Sciences, Tehran, Iran
- National Institute for Medical Research Development (NIMAD)
Zitieren
APA
Jafarzadeh, E., Montazeri, V., Aliebrahimi, S., Sezavar, A. H., Ghahremani, M. H., & Ostad, S. N. (2025). Targeting Cancer Stem Cells and Hedgehog Pathway: Enhancing Cisplatin Efficacy in Ovarian Cancer With Metformin. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70508
Vancouver
Jafarzadeh E, Montazeri V, Aliebrahimi S, Sezavar AH, Ghahremani MH, Ostad SN. Targeting Cancer Stem Cells and Hedgehog Pathway: Enhancing Cisplatin Efficacy in Ovarian Cancer With Metformin. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70508
BibTeX
@article{Jafarzadeh2025,
author = {Jafarzadeh, Emad and Montazeri, Vahideh and Aliebrahimi, Shima and Sezavar, Ahmad Habibian and Ghahremani, Mohammad H and Ostad, Seyed Nasser},
title = {Targeting Cancer Stem Cells and Hedgehog Pathway: Enhancing Cisplatin Efficacy in Ovarian Cancer With Metformin},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70508}
}
EUVIMED